Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options

The Trump administration is preparing to announce major autism initiatives, according to a report from the Washington Post. Federal health officials are expected to warn pregnant women about the risks of using acetaminophen, the active ingredient in Tylenol, particularly during early pregnancy unless treating a fever. The move follows recent studies, including an August review by Mount Sinai and Harvard, suggesting a potential link between prenatal acetaminophen use and an increased risk of autism in children.

Alongside this warning, the administration plans to spotlight leucovorin, a folate derivative commonly used to treat vitamin B9 deficiency, as a possible autism therapy. Early clinical trials have indicated that autistic children treated with leucovorin showed notable improvements in communication skills, leading some researchers to call the results promising.

President Donald Trump previewed the announcement on Sunday, describing it as “one of the biggest announcements medically in the history of our country.” The White House aims to position the initiative as a groundbreaking step in addressing autism, a condition affecting millions of children and families across the United States.

The National Institutes of Health (NIH) will also introduce a new autism data initiative. This program will fund 13 research teams to expand understanding of autism’s causes, treatments, and potential interventions. By combining caution on medication use during pregnancy with the promotion of innovative treatment options, the administration hopes to reshape public health policy on autism and accelerate scientific progress.

These upcoming announcements underscore growing concerns about environmental and pharmaceutical factors contributing to autism, while highlighting new possibilities for therapies that may improve the quality of life for affected children.